Xylem Inc. logo XYL - Xylem Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 19
HOLD 20
SELL 1
STRONG
SELL
0
| PRICE TARGET: $152.38 DETAILS
HIGH: $165.00
LOW: $130.00
MEDIAN: $158.50
CONSENSUS: $152.38
UPSIDE: 36.76%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 65% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Strong
Trading 50.8% above fair value
Current Price $111.42
Bear Case $59.10 47.0% downside ($59.10 - $111.42) / $111.42 = -47.0% $3.92 × 15x P/E
Fair Value $73.88 33.7% downside ($73.88 - $111.42) / $111.42 = -33.7% $3.92 × 19x P/E
Bull Case $88.65 20.4% downside ($88.65 - $111.42) / $111.42 = -20.4% $3.92 × 23x P/E

Adjust Assumptions

18.8x
3.92$

Key Value Driver

Normalized P/E multiple (19x base case)

Implied Market Multiple 28.4x

Plain-Language Summary

Applying a 19x P/E to adjusted EPS of $3.92, the base-case value is $73.88 per share. DDM cross-check: $329.35.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (40 analysts) $152.38
Analyst Range $130.00 – $165.00
Divergence from AlphaVal 52%

Warnings

Dividend-based valuation: $329.35 (above our primary estimate by 346%). Large gaps may signal the dividend doesn't reflect full earning power.
Wall Street's average price target is $152.38 (from 40 analysts). Our estimate is 52% below the consensus -- consider that gap carefully.

Key Risks

  • Growth DCF inappropriate — terminal value assumptions dominate
  • EV/EBITDA misleading for regulated businesses where capex is mandated
  • Regulatory risk is a fat tail not visible in normal multiples